The relationship between low prolactin and type 2 diabetes.
Hypoprolactinemia
Meta-analysis
Sex-specific analysis
Journal
Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588
Informations de publication
Date de publication:
18 May 2024
18 May 2024
Historique:
accepted:
08
05
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
aheadofprint
Résumé
Prolactin (PRL) is secreted throughout life in men and women. At elevated levels, its physiological role in pregnancy and lactation, and pathological effects, are well known. However clinical implications of low circulating PRL are not well established. We conducted a meta-analysis to examine the relationship between low PRL levels and type 2 diabetes. Five papers included cross-sectional studies comprising 8,720 men (mean age range 51.4-60 years) and 3,429 women (49.5-61.6 years), and four papers included cohort studies comprising 2,948 men (52.1-60.0 years) and 3,203 women (49.2-60.1 years). Individuals with pregnancy, lactation and hyperprolactinemia, drugs known to alter circulating PRL levels, or pituitary diseases had been excluded. Although most studies used quartiles to categorize PRL groups for analysis, PRL cut-off values (all measured by chemiluminescence immunoassay) were variably defined between studies: the lowest PRL quartiles ranged from 3.6 ng/ml to 7.2 ng/ml in men and between 4.5 ng/ml to 8 ng/ml in women; and the highest PRL quartiles ranged from 6.9 ng/ml to 13 ng/ml in men and 9.6 ng/ml to 15.8 ng/ml in women. Type 2 diabetes was defined variably using self-reported physician's diagnosis, fasting blood glucose, oral glucose tolerance test or glycated hemoglobin (HbA
Identifiants
pubmed: 38760578
doi: 10.1007/s11154-024-09886-w
pii: 10.1007/s11154-024-09886-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15(6):356–65. https://doi.org/10.1038/s41574-019-0194-6 .
doi: 10.1038/s41574-019-0194-6
pubmed: 30899100
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523–631. https://doi.org/10.1152/physrev.2000.80.4.1523 .
doi: 10.1152/physrev.2000.80.4.1523
pubmed: 11015620
Grattan DR. 60 years of neuroendocrinology: The hypothalamo-prolactin axis. J Endocrinol. 2015;226(2):T101–22. https://doi.org/10.1530/JOE-15-0213 .
doi: 10.1530/JOE-15-0213
pubmed: 26101377
pmcid: 4515538
Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169(6):575–81.
pubmed: 12975226
pmcid: 191295
Edinoff AN, Silverblatt NS, Vervaeke HE, et al. Hyperprolactinemia, clinical considerations, and infertility in women on antipsychotic medications. Psychopharmacol Bull. 2021;51(2):131.
pubmed: 34092827
pmcid: 8146565
Corona G, Mannucci E, Jannini EA, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009;6(5):1457–66. https://doi.org/10.1111/j.1743-6109.2008.01206.x .
doi: 10.1111/j.1743-6109.2008.01206.x
pubmed: 19210705
Balbach L, Wallaschofski H, Völzke H, Nauck M, Dörr M, Haring R. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Disord. 2013;21(13):12. https://doi.org/10.1186/1472-6823-13-12 .
doi: 10.1186/1472-6823-13-12
Wang T, Lu J, Xu Y, et al. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013;36(7):1974–80. https://doi.org/10.2337/dc12-1893 .
doi: 10.2337/dc12-1893
pubmed: 23340889
pmcid: 3687322
Chahar C, Chahar K, Ankit BS, Gadhwal A, Agrawal RP. Association of serum prolactin level with impaired glucose regulation and diabetes. J Assoc Physicians India. 2017;65(3):34–9.
pubmed: 28462541
Li J, Rice MS, Huang T, et al. Circulating prolactin concentrations and risk of type 2 diabetes in US women. Diabetologia. 2018;61(12):2549–60. https://doi.org/10.1007/s00125-018-4733-9 .
doi: 10.1007/s00125-018-4733-9
pubmed: 30306190
pmcid: 6309828
Wang T, Xu Y, Xu M, et al. Circulating prolactin and risk of type 2 diabetes: a prospective study. Am J Epidemiol. 2016;184(4):295–301. https://doi.org/10.1093/aje/kwv326 .
doi: 10.1093/aje/kwv326
pubmed: 27466075
Zhang Z, Piro AL, Allalou A, Alexeeff SE, Dai FF, Gunderson EP, Wheeler MB. Prolactin and maternal metabolism in women with a recent GDM pregnancy and links to future T2D: the SWIFT study. J Clin Endocrinol Metab. 2022;107(9):2652–65. https://doi.org/10.1210/clinem/dgac346 .
doi: 10.1210/clinem/dgac346
pubmed: 35666146
pmcid: 9387721
Faria de Castro L, Alves Dos Santos Á, Augusto Casulari L, Ansaneli Naves L, Amorim Amato A. Association between variations of physiological prolactin serum levels and the risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2020;166:108247. https://doi.org/10.1016/j.diabres.2020.108247 .
Han TS, Antonio L, Bartfai G, et al. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European Male Ageing Study. Rev Endocr Metab Disord. In press.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–9. https://doi.org/10.1016/j.rec.2021.07.010 .
doi: 10.1016/j.rec.2021.07.010
pubmed: 34446261
Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI. Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor (s). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current/chapter-04 . Accessed March 2024.
Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI manual for evidence synthesis. JBI; 2024. Available from: https://synthesismanual.jbi.global .
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor (s). Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane, 2021. https://training.cochrane.org/handbook/current/chapter-04 . Accessed March 2024.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186 .
doi: 10.1002/sim.1186
pubmed: 12111919
Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18(2): e1230. https://doi.org/10.1002/cl2.1230 .
doi: 10.1002/cl2.1230
pubmed: 36911350
pmcid: 8958186
Wagner R, Heni M, Linder K, et al. Age-dependent association of serum prolactin with glycaemia and insulin sensitivity in humans. Acta Diabetol. 2014;51(1):71–8. https://doi.org/10.1007/s00592-013-0493-7 .
doi: 10.1007/s00592-013-0493-7
pubmed: 23836327
Corona G, Wu FC, Rastrelli G, et al. EMAS study group. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the european male aging study (EMAS). J Sex Med. 2014;11(1):240–53. https://doi.org/10.1111/jsm.12327 .
doi: 10.1111/jsm.12327
pubmed: 24345293
Daimon M, Kamba A, Murakami H, et al. Association between serum prolactin levels and insulin resistance in non-diabetic men. PLoS ONE. 2017;12(4): e0175204. https://doi.org/10.1371/journal.pone.0175204 .
doi: 10.1371/journal.pone.0175204
pubmed: 28384295
pmcid: 5383244
Ruiz-Herrera X, de Los Ríos EA, Díaz JM, et al. Prolactin promotes adipose tissue fitness and insulin sensitivity in obese males. Endocrinology. 2017;158(1):56–68. https://doi.org/10.1210/en.2016-1444 .
doi: 10.1210/en.2016-1444
pubmed: 27805870
Ponce AJ, Galván-Salas T, Lerma-Alvarado RM, et al. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans. Endocrine. 2020;67(2):331–43. https://doi.org/10.1007/s12020-019-02170-x .
doi: 10.1007/s12020-019-02170-x
pubmed: 31919769
Sobrinho LG, Horseman ND. Prolactin and human weight disturbances: A puzzling and neglected association. Rev Endocr Metab Disord. 2019;20(2):197–206. https://doi.org/10.1007/s11154-019-09503-1 .
doi: 10.1007/s11154-019-09503-1
pubmed: 31062250
Barbarino A, De Marinis L, Mancini A, Farabegoli C. Estrogen-dependent plasma prolactin response to gonadotropin-releasing hormone in intact and castrated men. J Clin Endocrinol Metab. 1982;55(6):1212–6. https://doi.org/10.1210/jcem-55-6-1212 .
doi: 10.1210/jcem-55-6-1212
pubmed: 6813347
Park S, Kim DS, Daily JW, Kim SH. Serum prolactin concentrations determine whether they improve or impair β-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev. 2011;27(6):564–74. https://doi.org/10.1002/dmrr .
doi: 10.1002/dmrr
pubmed: 21557442
Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34(4):789–94. https://doi.org/10.2337/dc11-0064 .
doi: 10.2337/dc11-0064
pubmed: 21447659
pmcid: 3064029